Acelyrin — Merger or Acquisition (March 2025)
6 slides from Acelyrin's merger presentation, Mar 25, 2025
Slide 1: Alumis and Kaken Announce Dermatology Collaboration and License Agreement for ESK-001 in Japan
Transform Therapies. Reimagine Lives. March 25, 2025 Alumis and Kaken Announce Dermatology Collaboration and License Agreement for ESK - 001 in Japan
Slide 2: Forward-Looking Statements
2 © Alumis Forward - Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harb or” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates a nd e
Slide 3: Kaken Collaboration and Licensing Agreement Secures Key Market for ESK-001
© Alumis 3 Kaken Collaboration and Licensing Agreement Secures Key Market for ESK - 001 Global Commercialization Strategy Alumis - Kaken Collaboration for ESK - 001 in Dermatology in Japan 〉 Collaboration underscores ESK - 001’s commercial potential in PsO and leverages Kaken’s regional capabilities
Slide 4: Kaken Pharmaceutical Co., Ltd.: A Leading Japanese Dermatology Company
1 1 USD = 150.896 JPY (xe.com accessed March 24, 2025) Source: Kaken Pharmaceutical Co., Ltd. Corporate Report 2024 and investor relations materials. Confidential © Alumis 4 Kaken Pharmaceutical Co., Ltd. A Leading Japanese Dermatology Company Company Information INCORPORATED: 1948 HEAD OFFICE: Toky
Slide 5: Recent Achievements and Anticipated Multiple Near-Term Milestones
x x © Alumis 5 Recent Achievements and Anticipated Multiple Near - Term Milestones 2024 2025 2026 MAR24 APR24 JUL24 3Q24 YE24 ESK - 001 – Present Phase 2 STRIDE and OLE Data at AAD A - 005 – Phase 1 Initiation ESK - 001 – Initiate Phase 3 in PsO ESK - 001 – PsO OLE Data Update A - 005 – Phase 1 Data
Slide 6: Alumis: A Well Characterized Late-Stage Portfolio with Significant Opportunity
© Alumis 6 Alumis: A Well Characterized Late - Stage Portfolio with Significant Opportunity 〉 Collaboration with Kaken brings full commitment of a leading Japanese dermatology expert while maintaining optionality to maximize global value of ESK - 001 〉 Alumis ' announced merger with ACELYRIN on trac